

The flawed basis for FDA post-marketing safety decisions: the example of anti-depressants and children

Klein DF.

Neuropsychopharmacology

2006; 31(4):689-699

ARTICLE IDENTIFIERS

DOI: 10.1038/sj.npp.1300996

PMID: 16395296

PMCID: not available

JOURNAL IDENTIFIERS

LCCN: not available

pISSN: 0893-133X

eISSN: 1740-634X

OCLC ID: 15360199

CONS ID: not available

US National Library of Medicine ID: 8904907

This article was identified from a query of the SafetyLit database.